Aegis Capital has issued a ‘Buy’ rating and price target of $5 on Fennec Pharmaceuticals (OTCQB: FENCF). The specialty pharmaceuticals company recently reported its corporate update and financial results for the first quarter of 2017, including cash and cash equivalents on hand of $3.3 million, as of March 31, 2017. The analyst expects this should fund operations into 2018. The analyst also noted that the company’s potential new therapy for preventing cisplatin associated ototoxicity, Sodium Thiosulfate (STS), could fill a largely unmet need to avoid negative impact on quality of life. The company is preparing for NDA and MAA submissions, pending favorable SIOPEL 6 hearing results, which are expected in October 2017.
For more information, visit www.fennecpharma.com
About Fennec Pharmaceuticals
Fennec Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer